Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
作者信息
Tefferi A, Lim K-H, Abdel-Wahab O, Lasho T L, Patel J, Patnaik M M, Hanson C A, Pardanani A, Gilliland D G, Levine R L
出版信息
Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19.
Abstract
摘要
相似文献
1
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19.
2
[TET2 gene in hematological diseases].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):836-41. doi: 10.7534/j.issn.1009-2137.2014.03.049.
3
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Blood. 2011 Oct 27;118(17):4509-18. doi: 10.1182/blood-2010-12-325241. Epub 2011 Jul 29.
4
[TET2 as a gatekeeper for hematologic malignancies].
Rinsho Ketsueki. 2015 Jun;56(6):651-6. doi: 10.11406/rinketsu.56.651.
5
FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.
Med Oncol. 2013 Mar;30(1):483. doi: 10.1007/s12032-013-0483-1. Epub 2013 Feb 7.
6
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.
7
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.
8
Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016 Oct 10;38(5):583-588. doi: 10.3881/j.issn.1000-503X.2016.05.017.
9
Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802.
10
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Br J Haematol. 2012 Jan;156(1):67-75. doi: 10.1111/j.1365-2141.2011.08911.x. Epub 2011 Oct 24.
引用本文的文献
1
promotes clonal hematopoiesis in mice with loss of function.
Sci Adv. 2025 Aug 29;11(35):eadr5867. doi: 10.1126/sciadv.adr5867.
2
Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.
Clin Exp Med. 2025 Jun 13;25(1):202. doi: 10.1007/s10238-025-01742-8.
3
Progress Toward Epigenetic Targeted Therapies for Childhood Cancer.
Cancers (Basel). 2024 Dec 12;16(24):4149. doi: 10.3390/cancers16244149.
4
Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the Gene.
Life (Basel). 2024 May 16;14(5):637. doi: 10.3390/life14050637.
5
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Am J Hematol. 2024 Jun;99(6):1142-1165. doi: 10.1002/ajh.27271. Epub 2024 Mar 7.
6
Meta-analysis of the Prognostic Value of microRNA-22 in Leukemia Patients.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231212309. doi: 10.1177/15330338231212309.
7
Biological insights into the role of TET2 in T cell lymphomas.
Front Oncol. 2023 Sep 29;13:1199108. doi: 10.3389/fonc.2023.1199108. eCollection 2023.
8
Identification and interpretation of TET2 noncanonical splicing site intronic variants in myeloid neoplasm patients.
EJHaem. 2023 Jun 21;4(3):738-744. doi: 10.1002/jha2.744. eCollection 2023 Aug.
9
Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time.
Exp Hematol. 2023 Aug;124:45-55.e2. doi: 10.1016/j.exphem.2023.05.004. Epub 2023 May 22.
10
Characterization of global research hotspots and trends on ten-eleven translocation 2: visualization and bibliometric analysis.
Am J Transl Res. 2022 Dec 15;14(12):8504-8522. eCollection 2022.
本文引用的文献
1
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.
2
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.
Leukemia. 2009 May;23(5):900-4. doi: 10.1038/leu.2009.37. Epub 2009 Mar 5.
3
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
Leukemia. 2008 Apr;22(4):756-61. doi: 10.1038/sj.leu.2405097. Epub 2008 Jan 24.
4
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Leukemia. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Epub 2007 Sep 20.
Zotero 插件